Data gathered: June 29
Alternative Data for Ocugen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | 25 | Sign up | Sign up | Sign up |
| Patents | 4 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 85 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 155,406 | Sign up | Sign up | Sign up |
| Twitter Followers | 50,087 | Sign up | Sign up | Sign up |
| Twitter Mentions | 206 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 29 | Sign up | Sign up | Sign up |
| Lobbying Cost | $20,000 | Sign up | Sign up | Sign up |
| Business Outlook | 41 | Sign up | Sign up | Sign up |
| Linkedin Employees | 76 | Sign up | Sign up | Sign up |
About Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”.
| Price | $1.55 |
| Target Price | Sign up |
| Volume | 41,990,000 |
| Market Cap | $368M |
| Year Range | $0.36 - $1.98 |
| Dividend Yield | 0% |
| Revenue per Employee | $117,982 |
| Industry | Biotechnology |
In the news
 |
Reviewing Ocugen (NASDAQ:OCGN) and TRACON Pharmaceuticals (NASDAQ:TCON)June 26 - ETF Daily News |
 |
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?June 23 - Yahoo |
Ocugen, Inc.(NasdaqCM: OCGN) added to S&P Biotechnology Select Industry IndexJune 23 - Finnhub |
|
 |
Ocugen advances to high dose trial for Stargardt disease therapyJune 21 - Investing.com |
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt DiseaseJune 21 - GlobeNewswire |
|
Ocugen says DSMB approves high dose cohort dosing in OCU410ST studyJune 20 - Thefly.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 1M | 6.6M | -5.6M | -12M | -12M | -0.050 |
| Q4 '23 | 1.4M | 5.3M | 700,000 | -11M | -11M | -0.030 |
| Q3 '23 | 3.7M | 9.1M | -9.1M | -12M | -15M | -0.060 |
| Q2 '23 | 490,000 | 9.6M | -9.6M | -23M | -24M | -0.080 |
| Q1 '23 | 440,000 | 8.4M | -8.4M | -17M | -18M | -0.070 |
Insider Transactions View All
| Zhang Junge filed to buy 1,077,182 shares at $0.5. June 16 '23 |
| Musunuri Shankar filed to sell 2,190,073 shares at $1.1. February 17 '23 |
| Musunuri Shankar filed to sell 2,227,950 shares at $1.3. January 19 '23 |
| Musunuri Shankar filed to sell 752,540 shares at $1.4. December 20 '22 |
| Musunuri Shankar filed to sell 752,540 shares at $1.7. October 14 '22 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Christopher Jacobs Republican |
Dec 12, 22 | Sell | $1K - $15K |
| Christopher Jacobs Republican |
Jul 28, 22 | Buy | $15K - $50K |
Read more about Ocugen (OCGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Ocugen?
The Market Cap of Ocugen is $368M.
How Many People Work at Ocugen?
As of our latest update, Ocugen employed approximately 56 people worldwide. However, it's important to note that Ocugen's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Ocugen's revenue per employee?
$117,982. To calculate Ocugen's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Ocugen?
Currently, the price of one share of Ocugen stock is $1.55.
How can I analyze the OCGN stock price chart for investment decisions?
The OCGN stock price chart above provides a comprehensive visual representation of Ocugen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ocugen shares. Our platform offers an up-to-date OCGN stock price chart, along with technical data analysis and alternative data insights.
Does OCGN offer dividends to its shareholders?
As of our latest update, Ocugen (OCGN) does not offer dividends to its shareholders. Investors interested in Ocugen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ocugen?
Some of the similar stocks of Ocugen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.